Moreover, EGFR activation has been shown to drive KRasG12V-dependent pancreatic tumorigenesis in both mouse model of pancreatic cancer driven by mutant KRAS and human biopsies37, 38. This evidence concerns the gene KRAS and familial pancreatic carcinoma.